Endonovo Therapeutics, Inc. announced the full regulatory approval of its product, SofPulse® by the Taiwan Food and Drug Administration (TFDA), the regulatory division of the Ministry of Health and Welfare (MOHW). The approval is a significant accomplishment in introducing innovative Pulsed Electro Magnetic Field (PEMF) technology into the Taiwanese surgical market through Endonovo's valued distribution partner, EverMed Medical Enterprises Co. The SofPulse® TFDA approval marks the initial phase of Endonovo's expansion, through EverMed, into the largely untapped PEMF and surgical sectors in Taiwan.

Initial sales efforts will focus on introducing SofPulse® into multiple Taiwanese hospital surgical markets. EverMed will target four surgical specialties -- including cardiovascular surgery, orthopedic surgery, spinal surgery and plastic surgery -- representing hundreds of thousands of surgical cases. SofPulse® Commercialization in Taiwan: EverMed and Endonovo?s commercialization of SofPulse® in Taiwan commences with product registration with the NHI.

This will be followed by an extensive sales and marketing campaign to introduce surgeons and patients to the benefits of PEMF therapy. Sales and marketing strategies include leveraging existing connections with MD?s, surgeons, hospitals and medical facilities to promote the expansion of surgical applications across Taiwan's three regions. As healthcare professionals and patients experience the tangible benefits of PEMF technology in post-operative care, SofPulse® is poised for success and wide acceptance throughout the Taiwanese surgical market.

Taiwan FDA Process and International Expansion: The TFDA is the regulatory arm of Taiwan?s MOHW and is considered the driving force behind healthcare improvement in Taiwan. MOHW's focus is on promoting the health and well-being of all citizens in Taiwan by improving healthcare quality, advancing technological development, ensuring quality, efficiency, resource allocation contributing to international affairs. SofPulse® TFDA approval helps to validate Endonovo?s innovative approach to pain relief and non-opioid alternatives that has garnered widespread attention in the ever-growing global medical markets.